Table 3.

Time to second‐line antimyeloma treatment in the Asian subpopulation

	Rd continuous (n = 36)	Rd18 (n = 38)	MPT (n = 40)
Median time to second‐line AMT (95% CI), months	24·1 (18·6‐NE)	21·0 (11·1‐NE)	23·3 (11·9‐34·7)
HR (95% CI)
Rd continuous versus MPT		0·83 (0·44–1·55)
Rd continuous versus Rd18		0·85 (0·46–1·61)
Rd18 versus MPT		0·93 (0·50–1·73)

95% CI, 95% confidence interval; AMT, anti‐myeloma therapy; HR, hazard ratio; MPT, melphalan, prednisone, thalidomide; NE, not estimable; Rd continuous, lenalidomide plus low‐dose dexamethasone until disease progression; Rd18, lenalidomide plus low‐dose dexamethasone for 18 cycles.